Synergy Pharmaceuticals Inc fka SGYPQ

[Opti Mist]

Synergy Pharmaceuticals Reports Second Quarter 2017 Financial Results and Business Update


Print
Alert
Synergy Pharmaceuticals, Inc. (MM) (NASDAQ:SGYP)
Intraday Stock Chart
Today : Wednesday 9 August 2017

TRULANCE™ (plecanatide) U.S. net sales of $2.3 million in second quarter of 2017
Total TRULANCE monthly prescription volume has increased on average more than 182% month-over-month since launch in March 2017
TRULANCE supplemental new drug application (sNDA) for irritable bowel syndrome with constipation (IBS-C) accepted for FDA review - PDUFA date of January 24, 2018
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for the three months ended June 30, 2017. Synergy will host a conference call and webcast at 4:30 p.m. Eastern Time on Thursday, September 7, 2017 to discuss its corporate and financial strategy, and provide a general business update. Further details about this conference call can be found below.
“The first half of 2017 was a truly transformative period for Synergy, as we transitioned into a commercial organization and launched our first product, TRULANCE, in the U.S. for the treatment of adults with chronic idiopathic constipation (CIC),” said Gary S. Jacob, Ph.D., Chairman and CEO of Synergy Pharmaceuticals Inc. “We are pleased with the execution of our commercial strategy, and the strong initial demand for TRULANCE, reinforcing the need for new treatment options for patients suffering from CIC. And we are making significant progress in ensuring broad access to TRULANCE, highlighted by a number of favorable early decisions from key national payers.”
“During the second quarter, we also made significant progress towards broadening the TRULANCE label with the FDA acceptance of our sNDA for the treatment of adults with IBS-C,” continued Dr. Jacob. “These achievements put Synergy on excellent footing as we look to drive further long-term growth and value for the TRULANCE brand.”